Ipca Laboratory P. Ltd.
Click on the API name to know their properties
|Composit uses/ indication of Esokem-D :|
Acute nausea and vomiting, Dyspepsia, Functional dyspepsia, Gastric distension pain due to pressure on the stomach, Gastro-oesophageal reflux disease, Nausea and vomiting, Nausea and vomiting (chemotherapy induced), Nausea and vomiting (L-dopa induced), Non-ulcer dyspepsia, Reflux oesophagitis.
Dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and Zollinger-Ellison syndrome.
|Composit contra indication of Esokem-D :|
Allergy, Serious resistant GI mycoses, Hepatic impairment.
Hypersensitivity. It should not be co-administered with Methotrexate and atazanavir.
|Composit side effects of Esokem-D :|
Anaphylactic shock, angioedema, allergic reaction, increased prolactin levels, agitation, nervousness, extrapyramidal side effects, convulsions, somnolence, headache, gastro-intestinal disorders, transient intestinal Cramps, hives, itch, rash, galactorrhoea, excessive development of the breasts in males, amenorrhoea, ventricular arrhythmias, QTc prolongation, liver function test abnormal.
Headache, diarrhea, nausea, gas, decreased appetite, constipation, dry mouth, and abdominal pain. severe allergic reactions, chest pain, dark urine, fast heartbeat, fever, paresthesia, persistent sore throat, severe stomach pain, unusual bruising or bleeding, unusual tiredness, and yellowing of the eyes or skin.
|Composit caution of Esokem-D :|
Phaeochromocytoma, children below 2 yr, elderly, renal or hepatic impairment. Risk of cardiac arrhythmias and hypokalaemia if administered IV. Pregnancy and lactation.
Paediatric, pregnancy, lactation. Malignancy and hepatic impairment. Increased risk of developing certain infections such as community-acquired pneumonia.
Glaxo Smithkline Pharmaceuticals Ltd.